Emideltide narrowly voted down by FDA peptide advisory panel on Day 2 on July 24, 2026 Advisory Committees compounding pharmacies Delta Sleep-Inducing Peptide Emideltide Opioids PCAC Peptides sleep-inducing peptide Sleeplessness United States Food and Drug Administration Withdraw (activity) +
Nxera Pharma Reports Positive Phase 3 Results for Daridorexant in South Korea Insomnia Trial on January 22, 2026 daridorexant Nxera Pharma Phase 3 Quviviq Sleeplessness South Korea +